对性结肠炎的生物治疗与免疫性血小板缺血相关
Manabu Nagayama1,2, Yohei Funayama1, Osamu Taniguchi1
1Division of Gastroenterology, Department of Medicine, Jichi Medical University, Tochigi, Japan.
Clinical journal of gastroenterology
|July 31, 2024
概括
生物药物如乌斯特基努马布和阿达利努马布有效治疗耐火性性结肠炎 (UC) 和免疫血小板缩 (ITP). 这些疗法诱导大肠炎的缓解,改善血小板计数,可能防止手术.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 血液学 血液学 血液学
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性肠病.
- 肠外表现,如免疫性血栓缩 (ITP),可以发生在UC患者.
- 耐火性UC带来了重大的治疗挑战.
研究的目的:
- 报告一例耐火性性结肠炎 (UC) 病例与免疫性血小板减少 (ITP).
- 评估生物治疗在治疗这种复杂疾病中的有效性.
- 突出生物药物在控制肠道炎症和血液学异常方面的潜力.
主要方法:
- 一名51岁的男性患者患有耐火性UC和ITP,接受了生物药物治疗.
- 作为治疗干预措施,患者接受了乌斯特基努马布或阿达利努马布.
- 监测了临床结果,包括结肠炎活动和血小板计数.
主要成果:
- 生物治疗导致性结肠炎的临床缓解.
- 在患有ITP的患者中观察到血小板计数的显著改善.
- 患者的病情对乌斯特基努马布或阿达利努马布治疗反应良好.
结论:
- 生物药物在管理与ITP相关的耐火性UC方面表现出有效性.
- 这些药物可以有效控制并发性肠炎和血小板狭窄.
- 在某些特定情况下,生物疗法可能会为外科手术提供可行的替代方案.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
124
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
124
Drugs for Treatment of Ulcerative Colitis in IBD
133
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
133
Inflammatory Bowel Disease IV: Pharmacological Management
124
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
124
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
149
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
149
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
110
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
110
Inflammatory Bowel Disease I: Ulcerative Colitis
160
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
160


